Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on September 1, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi148
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/9/520    most recent
hyi148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Takiuchi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takiuchi, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received April 13, 2005
Accepted July 26, 2005

Original Article

Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002)

Hiroya Takiuchi 1*, Hiroyuki Narahara 2, Toshimasa Tsujinaka 3, Masahiro Gotoh 1, Sei-ichiro Kawabe 1, Ken-ichi Katsu 1, Hiroyasu Iishi 2, Masaharu Tatsuta 2, Kazumasa Fujitani 3, Hiroshi Furukawa 4, Tetsuo Taguchi 5, and for Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)

1 Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
2 Department of Gastroenterology, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan
3 Department of Surgery, Osaka National Hospital, Osaka, Japan
4 Department of Surgery, Sakai Municipal Hospital, Sakai, Osaka, Japan
5 Japan Society for Cancer Chemotherapy, Osaka, Japan

* To whom correspondence should be addressed.
Hiroya Takiuchi, E-mail: in2028{at}poh.osaka-med.ac.jp


  Abstract

Objective: A dose-escalation study of irinotecan (CPT-11) combined with S-1, a novel oral fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD) and dose-limiting toxicities (DLTs) in advanced gastric cancer.

Methods: S-1 was administered orally at 80 mg/m2/day for 21 consecutive days followed by a 2 week rest. CPT-11 was given intravenously on days 1 and 15 of each course, at an initial dose of 40 mg/m2/day, stepping up to 60, 80, 100 or 120 mg/m2/day depending on the DLT. Courses were repeated every 5 weeks, unless disease progression or severe toxicity was observed. At a level of the RD, five patients were added to conduct a pharmacokinetic (PK) study.

Results: A total of 24 patients were entered in this study. The MTD of CPT-11 was considered to be 100 mg/m2, because 50% of the patients (3/6) developed DLTs, diarrhea and rash. Therefore, the RD of CPT-11 was set at the dose immediately below 80 mg/m2. The overall response rate (RR) by the criteria of the Japanese Research Society of Gastric Cancer was 58.3% (14/24) and the RR at the RD was 66.7% (6/9), suggesting promising clinical efficacy. There were no significant differences between the PK parameters of S-1 on days 10 and 15.

Conclusions: S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer.

Keywords: S-1; irinotecan; combination chemotherapy; pharmacokinetics.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. Okamoto, T. Nishimura, M. Miyazaki, H. Yoshioka, A. Kubo, K. Takeda, N. Ebi, S. Sugawara, N. Katakami, M. Fukuoka, et al.
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Clin. Cancer Res., August 15, 2008; 14(16): 5250 - 5254.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ohtsu, S. Yoshida, and N. Saijo
Disparities in Gastric Cancer Chemotherapy Between the East and West
J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. A. Ajani
Evolving Chemotherapy for Advanced Gastric Cancer
Oncologist, October 1, 2005; 10(suppl_3): 49 - 58.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.